Aralast alpha1-Proteinase Inhibitor Surveillance Study
Information source: Baxter Healthcare Corporation
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alpha 1-Antitrypsin Deficiency
Intervention: ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Baxter Healthcare Corporation Official(s) and/or principal investigator(s):
Adupa Rao, MD, Principal Investigator, Affiliation: Coram
Summary
The primary objectives of this Phase 4, open label, prospective U. S. surveillance study are
to evaluate the health outcomes of AAT-deficient subjects who are initiating treatment with
ARALAST on patient-related outcomes (PRO), i. e., health-related quality of life (HRQoL),
healthcare resource utilization (HCRU), and various laboratory analyses to evaluate the
safety of long-term administration of ARALAST.
Up to 120 subjects will be enrolled and assessed for HRQoL and HCRU at baseline and every
6-months thereafter, for 2 years. A subset of subjects will be enrolled into the blood draw
portion of the study, which will also include assessments of antibodies to ARALAST, and
chemistry panel. Subjects will be treated according to the prescribing (attending)
physician's instructions based on the prescribing information given in the ARALAST package
insert.
Clinical Details
Official title: ARALAST alpha1-Proteinase Inhibitor (α1-PI) Surveillance Study
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: HRQoL and HCRU data
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or female 18 years of age or older
- Diagnosis of AAT deficiency associated emphysema
- Active prescription for augmentation therapy with ARALAST
- On service with Coram (a speciality pharmacy provider)
- Signed and dated informed consent
Exclusion Criteria:
- Clinically significant medical (other than COPD), psychiatric, or cognitive illness
that, in the opinion of Coram or the sponsor or the investigator, may compromise
subject safety or compliance (such as end stage renal or hepatic or heart disease, or
metastatic cancer or any difficulty in communicating over the telephone lines)
- Previous treatment with ARALAST (i. e. subjects who had previously received and then
discontinued ARALAST augmentation therapy and are now restarting ARALAST will be
excluded from the study)
Locations and Contacts
Adupa Rao, MD, San Marino, California 91108, United States
Additional Information
Starting date: June 2006
Last updated: February 5, 2008
|
